查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020559

2026-2034年全球急性細菌性皮膚和結構感染疾病（ABSSSI）治療市場規模、佔有率、趨勢和成長分析報告

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 167 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年，急性細菌性皮膚及皮膚結構感染疾病(ABSSSI) 治療市場規模將從 2025 年的 18 億美元成長至 28.7 億美元，並預計從 2026 年到 2034 年將以 5.32% 的複合年成長率成長。

由於影響皮膚及其下層的細菌感染疾病不斷增加，全球急性細菌性皮膚及皮膚結構感染疾病（ABSSSI）市場正在擴大。這些感染疾病的嚴重程度不一，從蜂窩組織炎炎等輕微病例到需要立即就醫的嚴重感染疾病均有涉及。有效的抗生素和先進的治療方法對於控制這些感染疾病和預防併發症至關重要。

抗生素抗藥性細菌的傳播是ABSSSI治療市場的主要促進因素之一。醫療專業人員正致力於研發和推廣能夠有效治療抗藥性感染疾病的新型抗菌療法。此外，住院和手術量的增加也推動了先進感染疾病治療方案需求的成長。

由於製藥公司持續增加對新型抗生素和標靶治療研發的投入，ABSSSI治療市場的未來前景依然光明。診斷技術的進步也有助於醫療專業人員及早發現感染疾病並提供及時治療。這些創新有望改善患者預後並促進市場成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球急性細菌性皮膚和結構感染疾病（ABSSSI）治療市場：依感染疾病類型分類

  • 市場分析、洞察與預測
  • 社區獲得性ABSSSI
  • 院內ABSSSI

第5章 全球急性細菌性皮膚和結構感染疾病（ABSSSI）治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 醣肽/醣肽
  • Oxazolidinone系列
  • BETA-內醯胺
  • 脂肽
  • 四環黴素
  • 其他藥物類別

第6章 全球急性細菌性皮膚和結構感染疾病（ABSSSI）治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 腸外
  • 口服
  • 外用

第7章 全球急性細菌性皮膚及結構性皮膚感染疾病（ABSSSI）治療市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球急性細菌性皮膚及結構性皮膚感染疾病（ABSSSI）治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie
    • Basilea Pharmaceutica
    • Cipher Pharmaceuticals
    • Endo Pharmaceuticals
    • Glenmark Pharmaceuticals
    • Melinta Therapeutics
    • Menarini Group
    • Merck
    • Nabriva Therapeutics
    • Paratek Pharmaceuticals
    • Pfizer
    • Sandoz
簡介目錄
Product Code: VMR112116263

The Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market size is expected to reach USD 2.87 Billion in 2034 from USD 1.80 Billion (2025) growing at a CAGR of 5.32% during 2026-2034.

The global acute bacterial skin and skin structure infections (ABSSSI) treatment market is expanding due to the increasing incidence of bacterial infections affecting the skin and underlying tissues. These infections can range from mild conditions such as cellulitis to severe infections that require immediate medical treatment. Effective antibiotics and advanced treatment options are essential to manage these infections and prevent complications.

One of the major drivers of the ABSSSI treatment market is the rising prevalence of antibiotic-resistant bacteria. Healthcare providers are focusing on developing and adopting new antimicrobial therapies that can effectively treat resistant infections. Additionally, the increasing number of hospital admissions and surgical procedures is contributing to the demand for advanced infection treatment solutions.

The future outlook for the ABSSSI treatment market remains promising as pharmaceutical companies continue to invest in research and development of new antibiotics and targeted therapies. Advances in diagnostic technologies are also helping healthcare professionals detect infections earlier and provide timely treatment. These innovations are expected to improve patient outcomes and support market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Infection Type

  • Community-Acquired ABSSSI
  • Hospital-Acquired ABSSSI

By Drug Class

  • Glycopeptides/Lipoglycopeptides
  • Oxazolidinones
  • Beta-lactams
  • Lipopeptide
  • Tetracyclines
  • Other Drug Classes

By Route of Administration

  • Parenteral
  • Oral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • AbbVie, Basilea Pharmaceutica, Cipher Pharmaceuticals, Endo Pharmaceuticals, Glenmark Pharmaceuticals, Melinta Therapeutics, Menarini Group, Merck, Nabriva Therapeutics, Paratek Pharmaceuticals, Pfizer, Sandoz
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY INFECTION TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Infection Type
  • 4.2. Community-Acquired ABSSSI Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Hospital-Acquired ABSSSI Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class
  • 5.2. Glycopeptides/Lipoglycopeptides Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Oxazolidinones Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Beta-lactams Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Lipopeptide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Tetracyclines Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Infection Type
    • 8.2.2 By Drug Class
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Infection Type
    • 8.3.2 By Drug Class
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Infection Type
    • 8.4.2 By Drug Class
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Infection Type
    • 8.5.2 By Drug Class
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Infection Type
    • 8.6.2 By Drug Class
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AbbVie
    • 10.2.2 Basilea Pharmaceutica
    • 10.2.3 Cipher Pharmaceuticals
    • 10.2.4 Endo Pharmaceuticals
    • 10.2.5 Glenmark Pharmaceuticals
    • 10.2.6 Melinta Therapeutics
    • 10.2.7 Menarini Group
    • 10.2.8 Merck
    • 10.2.9 Nabriva Therapeutics
    • 10.2.10 Paratek Pharmaceuticals
    • 10.2.11 Pfizer
    • 10.2.12 Sandoz